Vaccine banishes meningitis epidemic

Vial with syringe from Shutterstock
Vial with syringe from Shutterstock

The website of a global partnership formed to wipe out deadly meningitis epidemics in sub-Saharan Africa is closing down with a simple message: "Thank you and goodbye!"

Barely five years after the team began rolling out a tailor-made vaccine in Africa's "meningitis belt", the disease has all but disappeared there and the Meningitis Vaccine Project (MVP) is closing down after pioneering what may be a model for tackling infectious diseases in developing countries.

"We have not seen a single case among vaccinated populations ...," said Marie Pierre-Preziosi, MVP's director, "and transmission has stopped."

Read: Vaccine drives Africa meningitis cases down

The tale of MenAfriVac, made by Serum Institute of India and costing just 50 U.S. cents a shot, elicits hopeful comparisons with the current rush to develop a vaccine against Ebola:

A deadly disease needed tackling quickly at a price affordable to some of the world's poorest people; a committed group of scientists, drugmakers and philanthropists got together and developed a cheap, simple vaccine specifically for Africans; it was tested, trialled and deployed in record time; and in a matter of years, thousands of lives have been saved.

On Friday, the World Health Organisation (WHO) authorised MenAfriVac for use in routine child immunisations in Africa, establishing it as part of everyday healthcare and bringing an end into sight for a disease that has plagued Africa for more than a century.

Brain damage and death

Before MenAfriVac's introduction in 2010, people in a belt stretching from Senegal to Ethiopia were regularly afflicted by epidemics of the "A" strain of meningitis.

Meningococcal meningitis infects the thin lining surrounding the brain and spinal cord. It can cause severe brain damage, deafness, epilepsy or necrosis and, if untreated, is fatal in 50% of cases.

One of Africa's worst recorded outbreaks was in 1996-97, when some 250,000 were infected and more than 25,000 died in a few months.

Read: Meningitis survivors

An epidemic in Nigeria in 2008-09 saw 56,000 cases, almost three times the current total of Ebola cases in West Africa.

Yet five years on, meningitis A is rare in Africa. Jean-Marie Okwo-Bele, director of the WHO's immunisation department, called the introduction of MenAfriVac a "stunning success".

In 2010, he told a briefing of the "fear in the population" during seasonal outbreaks in the Democratic Republic of Congo, saying: "You can see empty streets because people are so afraid to be in contact with each other."

Cheaper and better

Back then, the available meningitis vaccines were broad-spectrum, targeting four strains, A, C, Y and W-135. They were also expensive, so in Africa were generally limited to emergency immunisation campaigns that were often too little, too late.

So African leaders urged global health experts to make something better – a vaccine costing no more than 50 U.S. cents that could specifically protect against the meningitis A that was claiming so many lives.

"African health officials told us: 'Don't come with a vaccine we cannot afford, because that would not be a solution'," Pierre-Preziosi said.

In record time, with focused drug research, committed partnerships and funding from the Bill & Melinda Gates Foundation, MVP bypassed big pharma firms and approached a cheaper generic drugmaker, Serum Institute of India, to develop a monovalent, or single-strain, meningitis A shot.

Read: Study finds that new vaccines may curb meningitis

It is the first vaccine made specifically for Africa, and the first not to need constant refrigeration, allowing it to be transported to remote areas in hot regions.

Since being introduced in Burkina Faso in 2010, it has been given to 215 million people across Benin, Cameroon, Chad, Ivory Coast, Ethiopia, Ghana, Mali, Niger, Mauritania, Nigeria, Senegal, Sudan, Togo and Gambia.

MVP's website features a valedictory film clip.

"It's quite short," says Pierre-Preziosi. "But in it, you will see the meningitis belt disappear."

Read More:
Man arrested for causing U.S. meningitis deaths
14 charged in deadly 2012 meningitis outbreak
New meningitis vaccine for African babies

Image: Vial with syringe from Shutterstock

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Nkosazana Dlamini-Zuma has got it in the bag
7% - 839 votes
I foresee a second term for Cyril Ramaphosa
83% - 9655 votes
Don’t discount a Zweli Mkhize win
10% - 1131 votes
Rand - Dollar
Rand - Pound
Rand - Euro
Rand - Aus dollar
Rand - Yen
Brent Crude
Top 40
All Share
Resource 10
Industrial 25
Financial 15
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.